about
Mesenchymal to amoeboid transition is associated with stem-like features of melanoma cells.Chromatin-associated CSF-1R binds to the promoter of proliferation-related genes in breast cancer cells.The colony-stimulating factor-1 (CSF-1) receptor sustains ERK1/2 activation and proliferation in breast cancer cell lines.Focal adhesion kinase (FAK) binds RET kinase via its FERM domain, priming a direct and reciprocal RET-FAK transactivation mechanism.GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors.Targeting RET-interleukin-6 crosstalk to impair metastatic dissemination in breast cancerTargeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts.Zoledronic acid impairs stromal reactivity by inhibiting M2-macrophages polarization and prostate cancer-associated fibroblasts.RET in breast cancer: functional and therapeutic implications.Metabolic implication of tumor:stroma crosstalk in breast cancer.Down-Regulation of SOX2 Underlies the Inhibitory Effects of the Triphenylmethane Gentian Violet on Melanoma Cell Self-Renewal and Survival.miR-155 Drives Metabolic Reprogramming of ER+ Breast Cancer Cells Following Long-Term Estrogen Deprivation and Predicts Clinical Response to Aromatase Inhibitors.Targeting stromal-induced pyruvate kinase M2 nuclear translocation impairs oxphos and prostate cancer metastatic spread.Senescent stroma promotes prostate cancer progression: the role of miR-210.Succinate dehydrogenase subunit B mutations modify human neuroblastoma cell metabolism and proliferation.Linking metabolic reprogramming to therapy resistance in cancer.Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase.Targeting the Metabolic Reprogramming That Controls Epithelial-to-Mesenchymal Transition in Aggressive Tumors.Nutrient Exploitation within the Tumor-Stroma Metabolic Crosstalk.Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance.Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells.The metabolic gene HAO2 is downregulated in hepatocellular carcinoma and predicts metastasis and poor survival.Metabolic reprogramming identifies the most aggressive lesions at early phases of hepatic carcinogenesisMetabolic shift toward oxidative phosphorylation in docetaxel resistant prostate cancer cellsCompartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer.Signaling Pathways Regulating Redox Balance in Cancer Metabolism.Stromal-induced downregulation of miR-1247 promotes prostate cancer malignancyPublisher Correction: Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancerCancer-associated fibroblasts promote prostate cancer malignancy via metabolic rewiring and mitochondrial transferLactate modulates CD4+ T-cell polarization and induces an immunosuppressive environment, which sustains prostate carcinoma progression via TLR8/miR21 axisLactate: A Metabolic Driver in the Tumour LandscapeGlucose Metabolic Reprogramming of ER Breast Cancer in Acquired Resistance to the CDK4/6 Inhibitor PalbociclibReprogramming of Amino Acid Transporters to Support Aspartate and Glutamate Dependency Sustains Endocrine Resistance in Breast CancerThyroid hormone inhibits hepatocellular carcinoma progression via induction of differentiation and metabolic reprogramming
P50
Q33617345-7D38087F-D303-4311-9AD8-70C19034906CQ34077207-95339FF3-AE84-4134-B733-F4727E8B51FFQ34077902-C6EA459D-9D78-4629-87C6-09ADF1F5F8E3Q34948215-BBD17B00-95CD-4B35-A4C8-6046CAAF2C56Q36940404-205AA32D-DF08-4269-A166-207869931948Q37690578-FCA2DF56-730B-471A-8C4E-2EAFABC6571CQ37697034-F92A4856-B076-4AFA-B357-CE5B7F047A36Q37702066-864634F2-4103-4ECC-80B0-B14F0806BAA2Q37830885-8E716111-FD02-4493-8EB4-7AFCE0C7DCEFQ38181405-EE3C4F51-6C35-46FC-BF23-1EDA78098811Q38760199-C558888C-8E3C-44CF-A4E5-057C127337FEQ38800885-7816B48C-1B52-4E99-95AC-0C578010886DQ38852121-9CAA8BF0-AFD2-4396-8981-0CB902FFA2C3Q38968807-574BC8FF-CB0A-44DD-B6A3-18790A3EB4A0Q39018519-B1595385-83F7-4417-80D6-759A51029599Q39075073-FCCE3994-C79A-42A0-AAD1-E9C7B96266DFQ39133395-A80A3D7E-2975-4FCF-B2C1-2C92CF2860A2Q39205930-7C7F9ED5-9CA0-4FB3-8386-1BA1B439660BQ39456875-853883FE-85C4-4346-A76F-86BC38D4A9CBQ39695658-0C4D3D1B-60AE-4006-89ED-0C05F69AD516Q40077017-E436193C-7352-4B2D-8372-AFFB76C3DC70Q41057110-A04D5B5E-21F2-499A-BB16-1717ACC479D1Q41561467-803DD747-E0FD-4395-B73A-13A833AAD63BQ42250126-911A7645-A5C4-4AB0-9019-26795CB8E979Q48239826-7A5F4D72-B6B4-4E16-8A99-A53E4A60E162Q54979494-4152E16A-D002-4DC0-AADA-3006FCB9FD17Q59386610-B4467112-0127-49FD-AB80-971F0DBAB0DEQ63884109-F170EA35-5971-4743-BD87-6DA52C8C8160Q63884166-E15C9DAB-3645-439B-A9F1-929891CA0F19Q63884168-58E66316-67AA-4A86-92B7-89A5B29A42D3Q63884170-809CFF23-61E4-4A88-BA4C-483BEE66438AQ90269084-ABC16A43-4C25-413B-83F4-CBD856AC2FB9Q91586214-E2048C6C-5235-46B6-88E3-5C871F5F7D88Q92745179-FEC0BC7A-9F7D-47E6-8177-51650831A86F
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Andrea Morandi
@ast
Andrea Morandi
@en
Andrea Morandi
@es
Andrea Morandi
@nl
type
label
Andrea Morandi
@ast
Andrea Morandi
@en
Andrea Morandi
@es
Andrea Morandi
@nl
prefLabel
Andrea Morandi
@ast
Andrea Morandi
@en
Andrea Morandi
@es
Andrea Morandi
@nl
P106
P1153
24341573500
P21
P2798
P31
P496
0000-0002-9222-5332